---
title: 'Regulatory Daily Summary: What Happened on November 19, 2026'
headline: FDA approves three treatments as UK proposes broader gene therapy rules
description: The FDA cleared drugs for Niemann-Pick disease, myasthenia gravis and
  Type 3 Gaucher disease. The White House also withdrew Heidi Overton’s nomination
  to lead the agency.
url: https://thebench.bio/news/regulatory/2026-11-19
topic: regulatory
date: '2026-11-19'
covers:
- '2026-11-19'
date_published: '2026-11-19T12:03:44Z'
date_modified: '2026-11-19T12:03:44Z'
tags:
- Regulatory
- Industry
sources: 7
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on November 19, 2026

**FDA approves three treatments as UK proposes broader gene therapy rules**

The FDA cleared drugs for Niemann-Pick disease, myasthenia gravis and Type 3 Gaucher disease. The White House also withdrew Heidi Overton’s nomination to lead the agency.

## Today in brief

Beren’s Lembaz won FDA approval to lower mortality risk in eligible patients with infantile-onset Niemann-Pick disease type C. [1] Regeneron’s Livsayis is now approved for some adults with myasthenia gravis, and Genzyme’s Infilbray for neurological symptoms of Type 3 Gaucher disease. [2] [3]

The UK government proposed bringing some synthetic therapies and genome-editing treatments under its gene therapy rules. [4]

The White House withdrew Heidi Overton’s FDA commissioner nomination ahead of a scheduled Senate committee consideration. [5] [6] [7]

## Lembaz approved to reduce mortality risk in Niemann-Pick disease

The FDA approved Beren’s Lembaz for patients who weigh at least 7 kg and whose neurological symptoms started before age 6. [1] The drug is indicated to reduce mortality risk in patients with infantile-onset Niemann-Pick disease type C. [1]

The approval relied on a survival analysis of 36 treated patients across three clinical studies and an expanded access program. [1] Compared with matched external controls, the analysis found a 55% lower mortality risk among treated patients. [1] Diagnosing the disease can take years, making it difficult to identify patients who may qualify for treatment. [1]

## UK proposal would bring some synthetic and genome-editing therapies under gene therapy rules

The UK proposed revising the legal definition of gene therapy medicines to cover certain synthetic therapies and genome-editing treatments under its existing advanced therapies framework. [4] The proposal would amend the Human Medicines Regulations 2012, subject to international notification procedures and parliamentary approval. [4]

The Medicines and Healthcare products Regulatory Agency and the Department of Health in Northern Ireland consulted on the changes for six weeks. Eighty-three percent of respondents supported them. [4] The government says the changes would clarify classification and regulatory requirements while keeping approval standards unchanged and avoiding reclassification of already licensed medicines. [4]

## Livsayis approved for adults with antibody-positive myasthenia gravis

The FDA approved Regeneron’s Livsayis for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies. [2] The siRNA therapy is injected under the skin four times a year. It is intended to lower circulating factor 5 and reduce terminal complement activation. [2]

In the ongoing Phase 3 NIMBLE trial, patients taking Livsayis improved 4.5 points on the Myasthenia Gravis-Activities of Daily Living scale at week 24, compared with 2.2 points on placebo. [2] The 2.3-point difference was statistically significant. [2] At least 5% of patients reported injection-site reactions, urinary tract infections or viral infections. [2]

## Infilbray becomes first approved treatment for neurological symptoms of Type 3 Gaucher disease

The FDA approved Genzyme’s Infilbray for neurological symptoms of Type 3 Gaucher disease in adults and children weighing at least 15 kg. [3] The oral drug crosses the blood-brain barrier and inhibits glucosylceramide synthase, an enzyme involved in harmful-substance buildup. [3]

In a 43-patient study, participants taking Infilbray improved on a combined measure of ataxia and cognitive function after 52 weeks, compared with patients receiving enzyme replacement therapy. [3] Reported risks include gastrointestinal and mood effects, suicidal thoughts and behavior, possible vision clouding in younger patients, and potential fetal-development harms during pregnancy. [3]

## White House withdraws Overton’s FDA commissioner nomination

The White House withdrew Heidi Overton’s nomination before the Senate committee’s scheduled consideration on November 18. [5] [6] [7] Three sources cited by Reuters said the nomination lacked sufficient congressional support. Senator Bill Cassidy said he believed Overton had enough support to pass both the committee and full Senate. [6] [7]

Kyle Diamantas remains acting head of the FDA. [6] A person familiar with discussions said Senator Roger Marshall had expressed interest in the role. Whether Marshall will be selected or secure Senate support remains uncertain. [7]

## The day in numbers

- **55%**: Lower mortality risk in the Lembaz survival analysis than among matched external controls. [1]
- **2.3 points**: Livsayis’s week-24 advantage over placebo on the myasthenia gravis activities-of-daily-living scale. [2]
- **83%**: UK consultation respondents who supported the proposed gene therapy definition changes. [4]

## Also published

- [UK modernises gene therapy definition in regulatory revamp](<https://pharmaphorum.com/news/uk-modernises-gene-therapy-definition-regulatory-revamp>), pharmaphorum
- [FDA clears Sanofi's Type 3 Gaucher therapy Infilbray](<https://pharmaphorum.com/news/fda-clears-sanofis-type-3-gaucher-therapy-infilbray>), pharmaphorum
- [ACT Brief: Trial Matching Nudges, Federal Pressures on Biotech, and FDA Leadership Vacancy](<https://www.appliedclinicaltrialsonline.com/view/trial-matching-federal-pressures-biotech-fda-leadership-vacancy>), Applied Clinical Trials
- [Bridging gaps in rare disease drug access requires strategic rethink ](<https://www.pharmaceutical-technology.com/news/bridging-gaps-rare-disease-drug-access/>), Pharmaceutical Technology
- [Overton wasn’t anyone’s first choice, but the alternative is likely to be much worse](<https://www.biocentury.com/article/661666/overton-wasn-t-anyone-s-first-choice-but-the-alternative-is-likely-to-be-much-worse?utm_source=bc_rss&utm_medium=rss>), BioCentury
- [Pharmaceutical Executive Daily: White House Withdraws FDA Nomination For Dr. Heidi Overton’s](<https://www.pharmexec.com/view/daily-white-house-withdraws-fda-nomination-dr-heidi-overton->), Pharmaceutical Executive
- [STAT+: 7 burning questions about the FDA’s post-Overton future](<https://www.statnews.com/2026/11/18/fda-after-heidi-overton-burning-questions-agency-future/?utm_campaign=rss>), STAT Biotech
- [White House pulls nomination for FDA nominee Overton](<https://www.biopharmadive.com/news/white-house-withdraw-heidi-overton-fda-commissioner-nomination/874961/>), BioPharma Dive
- [Beren's Niemann-Pick drug Lembaz cleared by FDA](<https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda>), pharmaphorum

## Sources

1. [With Lembaz approved, Beren turns to diagnosis and patient access](<https://www.biocentury.com/article/661663/with-lembaz-approved-beren-turns-to-diagnosis-and-patient-access?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-19
2. [FDA approves Regeneron’s Livsayis for generalised myasthenia gravis](<https://www.pharmaceutical-technology.com/news/fda-regenerons-livsayis-generalised-myasthenia-gravis/>), Pharmaceutical Technology, 2026-11-19
3. [FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease](<http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease>), FDA Press Announcements, 2026-11-18
4. [Government backs modernisation of gene therapy definitions](<https://www.gov.uk/government/news/government-backs-modernisation-of-gene-therapy-definitions>), MHRA, 2026-11-19
5. [White House drops Heidi Overton pick for FDA chief](<https://pharmaphorum.com/news/white-house-drops-heidi-overton-pick-fda-chief>), pharmaphorum, 2026-11-18
6. [Trump Pulls Overton's FDA Nomination Ahead of Senate HELP Vote](<https://www.pharmaceuticalcommerce.com/view/trump-pulls-overton-s-fda-nomination-ahead-of-senate-help-vote>), Pharmaceutical Commerce, 2026-11-18
7. [White House Withdraws Dr. Heidi Overton’s Nomination as FDA Commissioner: Report](<https://www.pharmexec.com/view/white-house-withdraws-dr-heidi-overton-nomination-fda-commissioner-report>), Pharmaceutical Executive, 2026-11-18

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661663/with-lembaz-approved-beren-turns-to-diagnosis-and-patient-access?utm_source=bc_rss&utm_medium=rss>
[2]: <https://www.pharmaceutical-technology.com/news/fda-regenerons-livsayis-generalised-myasthenia-gravis/>
[3]: <http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease>
[4]: <https://www.gov.uk/government/news/government-backs-modernisation-of-gene-therapy-definitions>
[5]: <https://pharmaphorum.com/news/white-house-drops-heidi-overton-pick-fda-chief>
[6]: <https://www.pharmaceuticalcommerce.com/view/trump-pulls-overton-s-fda-nomination-ahead-of-senate-help-vote>
[7]: <https://www.pharmexec.com/view/white-house-withdraws-dr-heidi-overton-nomination-fda-commissioner-report>
